Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
2010 Conversations With the Experts: Management of Iron Overload
The 15th Congress of the European Hematology Association was held 10–13 June 2010 in Barcelona, Spain. More than 2100 abstracts were submitted, which marks a new record for this annual congress. Join Dr. John Porter and our expert panel—Drs. Adlette C. Inati and Norbert Gattermann—as they identify and discuss the key abstracts and findings related to the management of iron overload. This panel discussion will focus on the latest data on iron overload in myelodysplastic syndromes, thalassaemia major and intermedia, and sickle cell disease, including specific commentary on transfusion intensity, trends in transfusion usage, combination therapy, compliance issues, cardiac iron overload, and other relevant issues.
|
|
Moderator
|
|
|
John B. Porter, MA, MD, FRCP
Professor, Department of Haematology
University College London
London, United Kingdom
|
|
|
Faculty
|
|
|
Norbert Gattermann, MD, PhD
Professor
Department of Haematology,
Oncology, and Clinical Immunology
Heinrich-Heine-University
Dusseldorf, Germany
|
|
|
|
Adlette C. Inati, MD
Head
Division of Pediatric Hematology-Oncology
Medical Director
Children's Center for Cancer and Blood Diseases
Rafik Hariri University Hospital
Beirut, Lebanon
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Apply an understanding of recent efficacy and safety clinical trial data on the use of iron chelation therapy to develop treatment strategies that will reduce the risk of clinical sequelae, including cardiac toxicity, in patients with thalassaemia major and intermedia, myelodysplastic syndromes, and sickle cell disease.
- Assess emerging insights regarding the practical aspects of managing iron overload, including improving patient satisfaction with and compliance to iron chelation therapy, and choosing appropriate dosing levels and titration schedules.
- Evaluate the role of iron overload markers in assessing the iron status of at-risk patients and monitoring response to iron chelation therapy.
|
Disclosure Information
John B. Porter, MA, MD, FRCP, has received grant/research support from and is on the speakers bureau of Novartis Pharmaceuticals Corporation; and is a consultant for Genzyme Corporation, Resonance Health Ltd, and Novartis Pharmaceuticals Corporation.
Norbert Gattermann, MD, PhD, is on the speakers bureau of and on the advisory boards for Novartis Pharmaceuticals Corporation and Pharmion Corporation.
Adlette C. Inati, MD, has no significant relationships to disclose.
This discussion may include unlabelled or unapproved uses of deferasirox, deferiprone, and deferrioxamine.
|
|
|
|
|
|
|
